CommercialCoverageMedium impact
06.02.27p, Assays of Genetic Expression in Tumor Tissue for Breast Cancer Prognosis (Independence Administrators)
Independence Blue Cross·Oncology, OB-GYN, General Surgery·Medical Policy
Effective date
Jan 1, 2025
We identified it
Jun 19, 2026
Summary
Independence Administrators updated their medical policy for genetic expression assays in tumor tissue for breast cancer prognosis, effective January 1, 2025. This is a commercial policy update that may affect coverage criteria or billing requirements for oncology-related genetic testing.
Action Required
By February 15, 2025: Billing team should review the complete policy document at the provided URL to identify specific changes to coverage criteria, prior authorization requirements, or billing guidelines for breast cancer genetic expression assays. Update billing protocols and provider documentation requirements as needed based on the full policy details.